Open AccessThe synergistic effects of 1, 2-epoxy-3 (3-(3, 4-dimethoxyphenyl)-4H-1-benzopiran-4on) propane and doxorubicin on breast cancer culture cell line
Author(s) -
Miranti Kania Dewi,
T. Rusmartini,
A.F. Sobandi,
Lelly Yuniarti
Publication year - 2020
Publication title -
journal of physics. conference series
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 85
eISSN - 1742-6596
pISSN - 1742-6588
DOI - 10.1088/1742-6596/1469/1/012011
Subject(s) - doxorubicin , breast cancer , mtt assay , cancer , cell culture , cancer cell , chemistry , medicine , in vitro , pharmacology , cancer research , chemotherapy , biology , biochemistry , genetics
Breast cancer is the second leading cause of death due to the low success rate of cancer treatment. Breast cancer therapy has not been maximized that encourage researchers to look for effective and selective cancer drugs. The purpose of this study was to determine at the synergistic effects of 1, 2-epoxy-3(3-(3, 4-dimethoxyphenyl)-4H-1-benzopiran-4on) propane (EPI) and doxorubicin on breast cancer cell cultures. This research is an experimental study in vitro, with a randomized study design post-test only control group design. The subject of this study was a T47D breast cancer cell culture, grown in a growth media with optimum time and incubation conditions. T47D are morphologically continuous cell lines like epithelial cells taken from breast tissue of a woman affected by ductal carcinoma. Cultures were performed using 30 wells, each well consisted of 1 x 106 cells. The results presented in the form of IC 50 using the Microculture Tetrazolium Salt (MTT) method and Combination index (CI) using compusyn software. An MTT method is a colorimetric assay based on cell metabolic activity. The results showed that the MTT method produced IC50 EPI values of 21.06μg/mL and doxorubicin 10.3μg/mL. EPI compounds in a combination of high concentrations have a CI below 1 (synergistic), whereas at high concentrations have CI above 1 (antagonistic). The conclusion of this study is that EPI compounds have weak anticancer in breast cancer and are synergistic with doxorubicin.